Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (ECOR) is a leader in non-invasive vagus nerve stimulation therapies, providing innovative solutions for neurological conditions and wellness applications. This page serves as the definitive source for ECOR news, offering investors and professionals timely updates on regulatory developments, clinical research, and strategic initiatives.
Access curated press releases covering FDA clearances, partnership announcements, and financial results. Stay informed about advancements in gammaCore™ therapies for migraine treatment and TAC-STIM cognitive enhancement technologies. Our repository includes updates on international expansions, clinical trial outcomes, and product pipeline developments.
Bookmark this page for direct access to primary source materials from electroCore, including neuromodulation research breakthroughs and commercialization progress across healthcare and defense sectors. Regular updates ensure you maintain current awareness of ECOR's position in the evolving bioelectronic medicine landscape.
electroCore (Nasdaq: ECOR) announced new data demonstrating the effectiveness of gammaCore non-invasive vagus nerve stimulation (nVNS) in treating concussion symptoms from mild traumatic brain injury (mTBI). The study, presented at the 2025 International Brain Injury Association World Congress, involved 102 patients and showed significant improvements in 22 out of 27 measured concussive symptoms.
Key findings revealed notable improvements in post-traumatic headache, nausea, dizziness, and depression. Importantly, the treatment showed similar effectiveness regardless of injury timing, benefiting both recent cases (under three months) and older injuries (over three years), suggesting neuromodulation's potential as a long-term treatment option.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in the upcoming Planet MicroCap Showcase at the Paris Hotel & Casino in Las Vegas on April 23 & 24, 2025.
CEO Dan Goldberger will deliver a group presentation on Wednesday, April 23, 2025, at 1:30 p.m. PT and will be available for one-on-one meetings throughout the event. Interested investors can schedule meetings through Planet MicroCap or by contacting electroCore's investor relations at ecor@fnkir.com.
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has achieved significant recognition by ranking #125 on the Financial Times' 'The Americas' Fastest Growing Companies 2025' list. The company secured this position based on its compound annual revenue growth between 2020 and 2023.
In the healthcare & life sciences sector, which represented 10% of the fastest-growing companies, electroCore ranked 16th among 30 healthcare companies, alongside notable peers like BeiGene, Hims & Hers Health, and Progyny. The company specializes in providing drug-free solutions for pain management, stress reduction, and sleep improvement.
The prestigious Financial Times ranking, now in its sixth year, was announced on April 2, 2025, featuring 300 top-performing companies across various sectors in the Americas.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in the upcoming Needham Virtual Healthcare Conference on April 10, 2025.
CEO Dan Goldberger and CFO Joshua Lev will deliver a group presentation at 2:15 p.m. ET and engage in one-on-one meetings throughout the conference day. The presentation will be accessible via live audio webcast, with a replay option available.
Investors interested in meeting with management during the conference can arrange meetings through their Needham representative or by contacting FNK IR at ecor@fnkir.com.
electroCore (ECOR) has secured a new five-year Federal Supply Schedule (FSS) contract with the Veterans Affairs (VA), effective from June 15, 2025, through June 14, 2030. The renewal comes after the VA's termination of 585 non-mission critical contracts, highlighting gammaCore's strategic importance.
The company reported accelerated revenue from VA hospitals in February and March 2025, following a slight slowdown in January, indicating sustained demand for their drug-free migraine treatment solution. The new contract includes provisions for prompt pay discounts and volume rebates for revenues exceeding $10 million per calendar year.
electroCore (ECOR) reported record financial results for full year 2024, achieving net sales of $25.2 million, a 57% increase from $16.0 million in 2023. The growth was primarily driven by an 85% increase in Rx gammaCore sales through VA/DOD channels and a 174% rise in Truvaga sales.
The company's net loss decreased by 37% to $11.9 million in 2024, with gross profit reaching $21.4 million at an 85% margin. Operating expenses totaled $33.6 million, including $2.4 million in R&D and $31.2 million in SG&A costs. Cash burn improved significantly, with net cash used in operations decreasing 53% to $7.0 million.
The company ended 2024 with $12.2 million in cash and equivalents, up from $10.6 million at the end of 2023. The adjusted EBITDA net loss improved to $9.0 million from $15.4 million in the previous year.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 12, 2025, after market close. The company will host a webcast and conference call at 5:30 PM EDT where management will discuss the financial results and conduct a Q&A session.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in two major investor conferences in March 2025.
The company will attend the 37th Annual Roth Conference from March 16-18 at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California, where Chief Financial Officer Joshua Lev will host one-on-one meetings with investors.
Additionally, electroCore will participate in LSI USA '25 from March 17-21 at the Waldorf Astoria Monarch Beach Resort in Dana Point, California, where CFO Joshua Lev will manage the company's exhibition presence.
Interested investors can schedule meetings through their Roth or LSI representatives or by contacting FNK IR at ecor@fnkir.com.
electroCore (NASDAQ: ECOR) has announced a distribution agreement with Spark Biomedical Inc. to distribute Sparrow Ascent™ within certain Department of Veterans Affairs (VA) facilities. Sparrow Ascent is an FDA-cleared non-invasive transcutaneous auricular neuromodulation device prescribed for treating opioid withdrawal symptoms.
The partnership aims to leverage electroCore's established distribution network to expand access to this drug-free, wearable neurostimulation solution for veterans. The Sparrow Ascent therapy complements electroCore's existing gammaCore™ therapy portfolio, offering VA customers a non-addictive treatment option for opioid withdrawal symptoms.
electroCore (NASDAQ: ECOR) has announced the availability of its flagship wellness product, Truvaga Plus, on Amazon's retail platform. The hand-held vagus nerve stimulator is designed to provide stress relief, improve sleep, enhance peace of mind, and improve focus through gentle vagus nerve activation.
CEO Dan Goldberger highlighted that the Amazon listing will help showcase their product to a broader audience through America's largest e-commerce marketplace, potentially increasing consumer accessibility and adoption.
